Filter by

Changing any of the form inputs will cause the list of events to refresh with the filtered results.

Filters applied
Series Type: Research and Innovation Speaker Series

Research and Innovation Speaker Series
Virtual
Research and Innovation Speaker Series
Virtual

Hunger, Food Security, and the Race to Produce New Seeds for a Climate-Changed World

Drawing on lessons from the mid-twentieth century efforts to rapidly increase food production, this session explores the urgent need for innovation in food production, highlighting the long-term impacts on the environment, health, and food security. Dr. Gabriela Soto Laveaga will discuss how this race for resilience will shape the future of global health and well-being. Dr. Megan Murray will moderate the conversation. The event is free and open to the public.

Research and Innovation Speaker Series
climate change
Research and Innovation Speaker Series
climate change

Research and Innovation Speaker Series
Research and Innovation Speaker Series

Innovation in the Treatment of Drug-resistant Tuberculosis: The endTB Clinical Trial

LEARN MORE/REGISTER In this Global Health Research and Innovations Speaker Series event, Dr. Carole Diane Mitnick, ScD, Professor of Global Health and Social Medicine at Harvard Medical School will share her work on the endTB clinical trial. Dr. Louise C. Ivers, MD, MPH, DTM&H, Faculty Director at the Harvard Global Health Institute, will moderate the conversation. PLEASE CLICK HERE TO REGISTER Event Description For decades, poor treatment options and low-quality evidence plagued care for rifampin-resistant tuberculosis (RR-TB). The advent of new anti-TB drugs and enhanced funding now permit randomized controlled trials of shortened, all-oral treatment for resistant TB. Methods endTB is an international, open-label, Phase 3 non-inferiority, randomized, controlled clinical trial to compare five 9-month all-oral regimens including bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C) and pyrazinamide (Z), to the standard (control) for treatment of fluoroquinolone-susceptible RR-TB. Participants were randomized to 9BLMZ, 9BCLLfxZ, 9BDLLfxZ, 9DCLLfxZ, 9DCMZ and control using Bayesian response-adaptive randomization. The primary outcome was favorable outcome at week 73 defined by two negative sputum culture results or by favorable bacteriologic, clinical, and radiologic evolution. The non-inferiority margin was 12 percentage points. Results Of 754 randomized patients, 696 and 559 were included in the modified intention to treat (mITT) and per-protocol (PP) analyses, respectively. In mITT, the control had 80.7% favorable outcomes. Regimens 9BCLLfxZ [adjusted risk difference (aRD): 9.5% (95% confidence interval (CI), 0.4 to 18.6)], 9BLMZ [aRD: 8.8% (95%CI, -0.6 to 18.2)], and 9BDLLfxZ [3.9% (95%CI, -5.8 to 13.6)] were non-inferior in mITT and in PP. The proportion of participants experiencing grade 3 or higher adverse events was similar across the regimens. Grade 3 or higher hepatotoxicity occurred in 11.7% of the experimental regimens overall and in 7.1% of the control. Conclusions The endTB trial increases treatment options for RR-TB with three shortened, all-oral regimens that were non-inferior to a current well-performing standard of care. PLEASE CLICK HERE TO REGISTER About the Speakers Carole Diane Mitnick, ScD, Professor of Global Health and Social Medicine, Harvard Medical School Dr. Mitnick is Professor of Global Health & Social Medicine at Harvard Medical School (HMS) and Associate Epidemiologist in the Division of Global Health Equity at Brigham & Women’s Hospital. She has 25 years of experience in programmatic support, research (observational and experimental), policy, and advocacy related to increased access to high-quality, appropriate treatment for TB, especially for drug-resistant TB. Dr. Mitnick works in close collaboration with Partners In Health, specifically in Peru, Haiti, Kazakhstan, and Lesotho. In addition to teaching at HMS and giving lectures at other institutions, Dr. Mitnick mentors trainees in the HMS Master of Medical Science in Global Health Delivery Program. She is the co-PI of the endTB and endTB-Q trials, two multi-country, Phase III, randomized, controlled, clinical trials of all-oral, shortened, novel regimens for rifampin-resistant TB. She has also recently begun conducting research on post-TB lung disease. Louise C. Ivers, MD, MPH, DTM&H, Faculty Director, Harvard Global Health Institute; Executive Director, Massachusetts General Hospital Center for Global Health Dr. Louise C. Ivers, MD, MPH, DTM&H is the Faculty Director of the Harvard Global Health Institute and the Executive Director of the Massachusetts General Hospital (MGH) Center for Global Health. Dr. Ivers is also the David Bangsberg Endowed Chair in Global Health Equity at MGH and a Professor of Medicine and Professor of Global Health and Social Medicine at Harvard Medical School. Dr. Ivers has spent her career providing care to the rural and urban poor and engaging in patient-oriented investigation that offer solutions to barriers to healthcare. She works on the design, implementation, and evaluation of large-scale public health programs in resource-limited settings with the goal of achieving health equity. She has worked on healthcare delivery in India, Southeast Asia, and Africa. From 2003-2017, Dr. Ivers served in various leadership roles for Partners in Health, including Clinical Director, Chief of mission, and Director of strategic implementation. In addition to expanding access to healthcare for the poor, Dr. Ivers has contributed to published research articles on HIV/AIDS, food insecurity, and cholera treatment and prevention and is involved in global policy and advocacy. About the Global Health Research and Innovation Speaker Series The Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond, to make cutting-edge research accessible to a diverse global audience, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health, followed by a moderated Q&A. Speakers will share their own perspectives; they do not speak for the university.

Research and Innovation Speaker Series
Research and Innovation Speaker Series

Research and Innovation Speaker Series

The Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond, to make cutting-edge research accessible to a diverse global audience, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health, followed by a moderated Q&A. Speakers will share their own perspectives; they do not speak for Harvard.
Research and Innovation Speaker Series
Research and Innovation Speaker Series

Global Health Research and Innovation Speaker Series with Milind Tambe

Virtual: Zoom
For over 15 years, Dr. Tambe and his team have been focused on AI for social impact, deploying end-to-end systems in areas of public health, conservation, and public safety. In this talk, he will highlight the results from their deployments for social impact in public health, as well as required innovations in integrating machine learning and optimization. Dr. Tambe will present recent results from their work in India with the world’s two largest mobile health programs for maternal and childcare that have served millions of beneficiaries, and on-going projects focused on other mobile health programs. Additionally, he will highlight results from an earlier project on HIV prevention among youth experiencing homelessness in Los Angeles. To address challenges of ML+optimization common to all of these applications, Dr. Tambe and his team have advanced the state of the art in decision-focused learning, restless multi-armed bandits and influence maximization in social networks. PLEASE CLICK HERE TO REGISTER   About Milind Tambe, PhD, MSc Dr. Milind Tambe is Gordon McKay Professor of Computer Science and Director of Center for Research on Computation and Society at Harvard University; concurrently, he is also Principal Scientist and Director for “AI for Social Good” at Google Research. Dr. Tambe is a recipient of the AAAI Award for Artificial Intelligence for the Benefit of Humanity, AAAI Feigenbaum Prize, IJCAI John McCarthy Award, AAAI Robert S. Engelmore Memorial Lecture Award, AAMAS ACM Autonomous Agents Research Award, INFORMS Wagner prize for excellence in Operations Research practice, Military Operations Research Society Rist Prize, and the Columbus Fellowship Foundation Homeland security award. Dr. Tambe is a fellow of AAAI and ACM. Dr. Tambe’s work focuses on advancing AI and multiagent systems for public health, conservation, and public safety, with a track record of building pioneering AI systems for social impact. You can read more about Dr. Milind Tambe on his website, X, LinkedIn, and Facebook.   About the Global Health Research and Innovation Speaker Series The Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond, to make cutting-edge research accessible to a diverse global audience, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health, followed by a moderated Q&A. Speakers will share their own perspectives; they do not speak for Harvard. PLEASE CLICK HERE TO REGISTER